Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

IMUNON Reports Compliance with Nasdaq Listing Requirements

April 11, 2024

IMUNON Reports 2023 Financial Results and Provides Business Update

March 28, 2024

IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses

March 25, 2024

Financial Events

Imunon’s Fourth Quarter 2023 Financial Results

March 28, 2024 at 10:00 AM EDT

Imunon’s Third Quarter 2023 Financial Results

November 14, 2023 at 10:00 AM EST